These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 17561422

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU, Bembenek SD, Szalma S.
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [Abstract] [Full Text] [Related]

  • 3. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists.
    Lorenzi S, Mor M, Bordi F, Rivara S, Rivara M, Morini G, Bertoni S, Ballabeni V, Barocelli E, Plazzi PV.
    Bioorg Med Chem; 2005 Oct 01; 13(19):5647-57. PubMed ID: 16085419
    [Abstract] [Full Text] [Related]

  • 4. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y, Liu H, Niu C, Luo C, Luo X, Shen J, Chen K, Jiang H.
    Bioorg Med Chem; 2004 Dec 01; 12(23):6193-208. PubMed ID: 15519163
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
    Rivara S, Mor M, Bordi F, Silva C, Zuliani V, Vacondio F, Morini G, Plazzi PV, Carrupt PA, Testa B.
    Drug Des Discov; 2003 Dec 01; 18(2-3):65-79. PubMed ID: 14675944
    [Abstract] [Full Text] [Related]

  • 6. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
    Istyastono EP, Nijmeijer S, Lim HD, van de Stolpe A, Roumen L, Kooistra AJ, Vischer HF, de Esch IJ, Leurs R, de Graaf C.
    J Med Chem; 2011 Dec 08; 54(23):8136-47. PubMed ID: 22003888
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A new class of histamine H3 receptor antagonists derived from ligand based design.
    Roche O, Rodríguez Sarmiento RM.
    Bioorg Med Chem Lett; 2007 Jul 01; 17(13):3670-5. PubMed ID: 17498953
    [Abstract] [Full Text] [Related]

  • 9. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Handley MK, Yates SL.
    J Pharmacol Exp Ther; 1999 May 01; 289(2):1160-8. PubMed ID: 10215700
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
    Wang XS, Tang H, Golbraikh A, Tropsha A.
    J Chem Inf Model; 2008 May 01; 48(5):997-1013. PubMed ID: 18470978
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
    Zheng M, Zhang Z, Zhu W, Liu H, Luo X, Chen K, Jiang H.
    Bioorg Med Chem; 2006 May 15; 14(10):3428-37. PubMed ID: 16458008
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q, Yang J, Liang K, Feng L, Li S, Wan J, Xu X, Yang G, Liu D, Yang S.
    J Chem Inf Model; 2008 Sep 15; 48(9):1802-12. PubMed ID: 18707092
    [Abstract] [Full Text] [Related]

  • 16. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
    Lescot E, Sopkova-de Oliveira Santos J, Colloc'h N, Rodrigo J, Milazzo-Segalas I, Bureau R, Rault S.
    Proteins; 2008 Oct 15; 73(1):173-84. PubMed ID: 18409194
    [Abstract] [Full Text] [Related]

  • 17. Computational study of histamine H3-receptor antagonist with support vector machines and three dimension quantitative structure activity relationship methods.
    Chen HF.
    Anal Chim Acta; 2008 Aug 29; 624(2):203-9. PubMed ID: 18706326
    [Abstract] [Full Text] [Related]

  • 18. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
    Morini G, Comini M, Rivara M, Rivara S, Lorenzi S, Bordi F, Mor M, Flammini L, Bertoni S, Ballabeni V, Barocelli E, Plazzi PV.
    Bioorg Med Chem Lett; 2006 Aug 01; 16(15):4063-7. PubMed ID: 16713264
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
    Bissantz C, Bernard P, Hibert M, Rognan D.
    Proteins; 2003 Jan 01; 50(1):5-25. PubMed ID: 12471595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.